Celltrion expands Japan push with SteQeyma IV launch

Celltrion said Friday it has launched the intravenous formulation of SteQeyma for autoimmune diseases in Japan.

Opens the original publisher in a new tab. Full articles belong to their publishers; a subscription may be required.